Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
99% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. PGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PGNX' s Cash to Debt Range Over the Past 10 Years
Min: 65  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.65
PGNX's Equity to Asset is ranked lower than
54% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PGNX: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
PGNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.89 Max: 0.98
Current: 0.65
0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
99% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -0.48
M-Score: 52.68
WACC vs ROIC
21.07%
-431.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -383.84
PGNX's Operating margin (%) is ranked lower than
68% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. PGNX: -383.84 )
Ranked among companies with meaningful Operating margin (%) only.
PGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 12.17
Current: -383.84
-878.82
12.17
Net-margin (%) -381.62
PGNX's Net-margin (%) is ranked lower than
69% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. PGNX: -381.62 )
Ranked among companies with meaningful Net-margin (%) only.
PGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 12.24
Current: -381.62
-876.82
12.24
ROE (%) -42.69
PGNX's ROE (%) is ranked lower than
58% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. PGNX: -42.69 )
Ranked among companies with meaningful ROE (%) only.
PGNX' s ROE (%) Range Over the Past 10 Years
Min: -87.75  Med: -33.65 Max: 16.86
Current: -42.69
-87.75
16.86
ROA (%) -30.42
PGNX's ROA (%) is ranked lower than
53% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. PGNX: -30.42 )
Ranked among companies with meaningful ROA (%) only.
PGNX' s ROA (%) Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: -30.42
-79.08
14.53
ROC (Joel Greenblatt) (%) -1720.96
PGNX's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. PGNX: -1720.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1585.16  Med: -413.77 Max: 208.07
Current: -1720.96
-1585.16
208.07
Revenue Growth (3Y)(%) -32.50
PGNX's Revenue Growth (3Y)(%) is ranked lower than
79% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. PGNX: -32.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: -16.70 Max: 73.8
Current: -32.5
-55.5
73.8
EBITDA Growth (3Y)(%) -17.30
PGNX's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. PGNX: -17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PGNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.4  Med: -8.10 Max: 51.1
Current: -17.3
-46.4
51.1
EPS Growth (3Y)(%) -18.10
PGNX's EPS Growth (3Y)(%) is ranked lower than
65% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. PGNX: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PGNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.5  Med: -6.15 Max: 221.1
Current: -18.1
-73.5
221.1
» PGNX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

PGNX Guru Trades in Q2 2015

Chuck Royce 3,221,850 sh (+88.65%)
Paul Tudor Jones 2,387,708 sh (+1.93%)
Murray Stahl 67,200 sh (unchged)
Julian Robertson Sold Out
» More
Q3 2015

PGNX Guru Trades in Q3 2015

Ken Fisher 83,250 sh (New)
Paul Tudor Jones 2,392,099 sh (+0.18%)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 2,978,950 sh (-7.54%)
» More
Q4 2015

PGNX Guru Trades in Q4 2015

Ken Fisher 140,191 sh (+68.40%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,370,760 sh (-0.89%)
Chuck Royce 2,282,250 sh (-23.39%)
» More
Q1 2016

PGNX Guru Trades in Q1 2016

Ken Fisher 140,191 sh (unchged)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,364,488 sh (-0.26%)
Chuck Royce 2,138,350 sh (-6.31%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ENTA, NAS:MYOK, NAS:GERN, OTCPK:PTCHF, NAS:ACRS, NAS:AGEN, NAS:OMER, NAS:MNKD, NAS:ARNA, NAS:SGMO, NAS:AMRN, NAS:TLGT, OTCPK:ZLDPF, NAS:OTIC, NAS:XNPT, NAS:CYTK, NAS:SPPI, NAS:RVNC, NAS:CTMX, NAS:NDRM » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc is engaged in the development of medicines for oncology. The Company develops products for the treatment of prostate cancer, opioid-induced constipation, or OIC, as well as OIC for non-cancer pain.

Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.

Ratios

vs
industry
vs
history
Forward P/E 50.00
PGNX's Forward P/E is ranked lower than
89% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 21.32 vs. PGNX: 50.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.27
PGNX's P/B is ranked lower than
70% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. PGNX: 5.27 )
Ranked among companies with meaningful P/B only.
PGNX' s P/B Range Over the Past 10 Years
Min: 1.08  Med: 3.54 Max: 8.82
Current: 5.27
1.08
8.82
P/S 37.97
PGNX's P/S is ranked lower than
71% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. PGNX: 37.97 )
Ranked among companies with meaningful P/S only.
PGNX' s P/S Range Over the Past 10 Years
Min: 1.88  Med: 9.63 Max: 177.27
Current: 37.97
1.88
177.27
Current Ratio 6.44
PGNX's Current Ratio is ranked higher than
61% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PGNX: 6.44 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.68 Max: 32.92
Current: 6.44
2.67
32.92
Quick Ratio 6.44
PGNX's Quick Ratio is ranked higher than
62% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. PGNX: 6.44 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.68 Max: 32.92
Current: 6.44
2.67
32.92
Days Sales Outstanding 81.67
PGNX's Days Sales Outstanding is ranked lower than
63% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. PGNX: 81.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.36  Med: 32.86 Max: 180.24
Current: 81.67
0.36
180.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.94
PGNX's Price/Net Cash is ranked lower than
82% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. PGNX: 17.94 )
Ranked among companies with meaningful Price/Net Cash only.
PGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.59  Med: 6.30 Max: 22.41
Current: 17.94
1.59
22.41
Price/Net Current Asset Value 13.45
PGNX's Price/Net Current Asset Value is ranked lower than
80% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. PGNX: 13.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.48  Med: 5.74 Max: 18.68
Current: 13.45
1.48
18.68
Price/Tangible Book 12.08
PGNX's Price/Tangible Book is ranked lower than
83% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. PGNX: 12.08 )
Ranked among companies with meaningful Price/Tangible Book only.
PGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.22  Med: 5.05 Max: 13.49
Current: 12.08
1.22
13.49
Price/Median PS Value 3.95
PGNX's Price/Median PS Value is ranked lower than
92% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. PGNX: 3.95 )
Ranked among companies with meaningful Price/Median PS Value only.
PGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.27 Max: 13.62
Current: 3.95
0.24
13.62
Earnings Yield (Greenblatt) (%) -12.01
PGNX's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. PGNX: -12.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.01  Med: 1.80 Max: 10.2
Current: -12.01
-12.01
10.2

More Statistics

Revenue (TTM) (Mil) $10.88
EPS (TTM) $ -0.59
Beta2.60
Short Percentage of Float18.23%
52-Week Range $3.61 - 11.15
Shares Outstanding (Mil)69.95

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 73 73 166
EPS ($) 0.12 -0.32 1.08
EPS w/o NRI ($) 0.12 -0.32 1.08
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4 Jul 22 2016
Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4 Jul 22 2016
ETF’s with exposure to Progenics Pharmaceuticals, Inc. : July 21, 2016 Jul 21 2016
Why Valeant, Progenics, Ryerson, Zafgen and TerraForm Are On The Move Today Jul 20 2016
These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy? Jul 20 2016
Progenics (PGNX) Stock Soars as Relistor Receives FDA Approval Jul 20 2016
Valeant Pharmaceuticals: Two for Two Jul 20 2016
Valeant (VRX) Stock Gains as FDA Approves Anticonstipation Drug Jul 20 2016
Could This Be the Turning Point for Progenics and Valeant? Jul 20 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2016
Valeant Gets FDA OK for Anticonstipation Tablets Developed by Progenics Jul 19 2016
Valeant, Progenics shares rise on constipation drug approval Jul 19 2016
Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced... Jul 19 2016
Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced... Jul 19 2016
Top 3 Biotech Companies Awaiting FDA Approval Jul 12 2016
Progenics Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 08 2016
Progenics Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 08 2016
Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3% Jul 07 2016
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US :... Jul 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)